Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.
Wilkerson AD, Parthasarathy PB, Stabellini N, Mitchell C, Pavicic PG Jr, Fu P, Rupani A, Husic H, Rayman PA, Swaidani S, Abraham J, Budd GT, Moore H, Al-Hilli Z, Ko JS, Baar J, Chan TA, Alban T, Diaz-Montero CM, Montero AJ.
Wilkerson AD, et al. Among authors: mitchell c.
Clin Cancer Res. 2024 Jan 5;30(1):82-93. doi: 10.1158/1078-0432.CCR-23-1349.
Clin Cancer Res. 2024.
PMID: 37882661
Free PMC article.
Clinical Trial.